Square Pharmaceuticals PLC
DDSE:SQURPHARMA219.60
BDT
+0.80
(+0.37%)
ISIN
BD0473SQPH00
Return %
Stock
S&P 500
1Y
2.91
14.39
3Y
3.58
81.42
5Y
-5.02
68.62
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Tapan M. A. Chowdhury
- Full Time Employees
- 15,937
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dhaka Bangladesh
- IPO Date
- Feb 23, 1995
- Website
- squarepharma.com.bd
- Similar Companies
- Business
- Square Pharmaceuticals PLC is a Bangladesh-based healthcare and pharmaceutical manufacturing company engaged in the development, manufacturing, marketing, and distribution of generic finished dosage formulations, active pharmaceutical ingredients (APIs), biologicals, herbal remedies, and animal healthcare products. Founded in 1958 and headquartered in Dhaka, Bangladesh, the company operates as the flagship enterprise of Square Group and serves retail pharmacies, hospitals, government healthcare institutions, and international distributors. Its human healthcare portfolio spans multiple therapeutic categories and dosage forms, encompassing alimentary tract and metabolism treatments including proton pump inhibitors, antacids, and antidiabetics; cardiovascular drugs such as antihypertensives, lipid-lowering agents, and antianginals; systemic anti-infectives comprising cephalosporins, penicillins, macrolides, and fluoroquinolones; central nervous system therapies including antidepressants, anxiolytics, and antiepileptics; respiratory preparations encompassing antihistamines, bronchodilators, and antiasthmatics; musculoskeletal drugs including non-steroidal anti-inflammatory drugs and muscle relaxants; specialized oncology medications; and biopharmaceutical formulations such as insulins and biosimilars. The company markets these treatments in various delivery systems, including oral solid tablets and capsules; oral liquids and suspensions; sterile parenterals and lyophilized injectables; ophthalmic drops; topical ointments and creams; metered-dose inhalers; and nasal sprays. Beyond human pharmaceuticals, the company manufactures herbal and nutraceutical supplements; veterinary medicines, feed additives, and crop care solutions through its agrovet division; basic chemicals and APIs through dedicated synthesis units; and contract manufacturing services for multinational healthcare corporations. Square Pharmaceuticals conducts commercial operations through production facilities in Pabna and Gazipur, Bangladesh, and maintains regulatory approvals from authorities such as the US FDA and UK MHRA, exporting finished pharmaceuticals to more than 45 countries across Asia, Africa, Europe, Oceania, and the Americas. The company operates key subsidiaries and affiliated entities including Square Formulations Ltd, Square Lifesciences Ltd, Square Cephalosporins Ltd, and Square Pharmaceuticals Kenya EPZ Ltd. In recent developments, the company announced a Tk 650 crore capital expenditure program focused on balancing, modernization, rehabilitation, and expansion (BMRE) across its manufacturing infrastructure to accelerate production capacity for high-margin biosimilars, advanced oncology therapies, and chronic illness medications. Furthermore, its international subsidiary Square Pharmaceuticals Kenya EPZ Ltd completed the operational ramp-up of its major manufacturing plant in Athi River, Kenya, achieving commercial profitability and expanding regional supply of essential medicines across the East African Community.